Wednesday, March 30, 2011

UNITED THERAPEUTICS IS AMONG THE COMPANIES IN THE BIOTECHNOLOGY INDUSTRY WITH THE HIGHEST EPS GROWTH (UTHR, GENZ, ALXN, CELG, CEPH)

Mar 30, 2011 (SmarTrend(R) News Watch via COMTEX) -- Below are the top 5 companies in the Biotechnology industry ranked by the year-over-year expected EPS growth rate. The long-term growth rate is the expected annual increase in operating EPS over the next three to five years.
United Therapeutics (NASDAQ:UTHR) EPS is expected to grow 283.1% year-over-year, better than the company's long-term growth rate of 60%. Based on the forward P/E of 12.7x its PEG ratio is 0.21, which signifies a discount in value relative to growth.
Genzyme (NASDAQ:GENZ) EPS is expected to grow 234.8% year-over-year, better than the company's long-term growth rate of 19.3%. Based on the forward P/E of 18.6x its PEG ratio is 0.96, which signifies a discount in value relative to growth.
Alexion Pharmaceuticals (NASDAQ:ALXN) EPS is expected to grow 118.3% year-over-year, better than the company's long-term growth rate of 38.8%. Based on the forward P/E of 43.9x its PEG ratio is 1.13, which signifies a premium valuation given for growth.
Celgene (NASDAQ:CELG) EPS is expected to grow 60% year-over-year, better than the company's long-term growth rate of 25.7%. Based on the forward P/E of 16.4x its PEG ratio is 0.64, which signifies a discount in value relative to growth.
Cephalon (NASDAQ:CEPH) EPS is expected to grow 49.3% year-over-year, better than the company's long-term growth rate of 10.2%. Based on the forward P/E of 7x its PEG ratio is 0.68, which signifies a discount in value relative to growth.
SmarTrend currently has shares of Genzyme in an Uptrend and issued the Uptrend alert on July 23, 2010 at $60.20. The stock has risen 26.3% since the Uptrend alert was issued.

No comments:

Post a Comment

Recent Comments

Powered By Blogger